Framingham Heart Study Brain Aging Program to Host Clinical Neuropathology Case Conference
The Framingham Heart Study Brain Aging Program will host its upcoming Clinical Neuropathology Case Conference on April 10, 2026, from 10:00 AM to 12:00 PM.
This interactive session, organize
d by the program’s Clinical and Neuropathology Cores, will feature four compelling cases highlighting clinical history, neuroimaging, and neuropathological findings. Each case will explore the alignment—and at times discrepancy—between clinical diagnoses and neuropathological outcomes, fostering discussion aimed at improving diagnostic accuracy.
These conferences play a vital role in strengthening collaboration between clinical and neuropathology teams, ultimately contributing to more precise assessment methods and advancing future treatments in brain aging and neurodegenerative disease.
The event will be held virtually. Registration is required.
https://bu-hipaa.zoom.us/webinar/register/WN_6WHzlVaCRTKns67a9Sv-EQ#/registration
Cross-Sectional Association Between Blood Cell Phenotypes, Cognitive Function, and Brain Imaging Measures in the Community-Based Framingham Heart Study
Fang Y, Doyle MF, Alosco ML, Mez J, Satizabal CL, Qiu WQ, Lunetta KL and Murabito JM: Cross-sectional association between blood cell phenotypes, cognitive function and brain imaging measures in the community-based Framingham Heart Study. J Alzheimers Dis. 2022; 87(3):1291-1305.
Life-Course Factors and Social Disparities of Dementia
May 17, 2022
Sponsored by BU Alzheimer’s Disease Center, BU Evans Center for Interdisciplinary Biomedical Research, American Heart Association, and the Framingham Heart Study Brain Aging Program.
Interface astrogliosis in contact sport head impacts and military blast exposure
Babcock KJ, Abdolmohammadi B, Kiernan PT, Mahar I, Cherry JD, Alvarez VE, Goldstein LE, Stein TD, McKee AC, Huber BR. Interface astrogliosis in contact sport head impacts and military blast exposure. Acta Neuropathol Commun. 2022 Apr 13;10(1):52.
Dr. Xiaoling Zhang interview with Medical News Today: Risk of Alzheimer’s linked to cholesterol, blood sugar levels at age 35
Dr. Xiaoling Zhang interviewed with Annie Lennon from Medical News Today, and discussed about the recent study published in Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association, Farmingham Heart Study.
Dr. Farrer Interview with CNN: Fight Alzheimer’s in your mid-30s by tracking these warning signs
On Wednesday, March 23, 2022, Dr. Lindsay Farrer interviewed with Sandee LaMotte from CNN, and discussed about the recent study published in Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association, Farmingham Heart Study.
Midlife lipid and glucose levels are associated with Alzheimer’s disease
Zhang X, Tong T, Chang A, Ang TFA, Tao Q, Auerbach S, Devine S, Qiu WQ, Mez J, Massaro J, Lunetta KL, Au R, Farrer LA. Midlife measures of high-density lipoprotein and fasting glucose are associated with late-onset Alzheimer disease. Alzheimer Dement. 2023; 19:181-193.
A comparison between tau and amyloid-β cerebrospinal fluid biomarkers in chronic traumatic encephalopathy and Alzheimer disease
Turk KW, Geada A, Alvarez VE, Xia W, Cherry JD, Nicks R, Meng G, Daley S, Tripodis Y, Huber BR, Budson AE, Dwyer B, Kowall NW, Cantu RC, Goldstein LE, Katz DI, Stern RA, Alosco ML, Mez J, McKee AC, Stein TD. A comparison between tau and amyloid- cerebrospinal fluid biomarkers in Chronic Traumatic Encephalopathy and Alzheimer disease. Alzheimers Res Ther. 2022; 14(1):28.
Protein phosphatase 2A and complement component 4 are linked to the protective effect of APOE ɛ2 for Alzheimer’s disease
Jun GR, Zhu C, Chung J, Panitch R, Hu J, The Alzheimer’s Disease Genetics Consortium, Foroud TM, Wang L-S, Ertekin-Taner N, Bennett DA, Haines JL, Mayeux RP, Pericak-Vance MA, Schellenberg GD, Lunetta KL, Ikezu T, Stein TD, Farrer LA. Protein phosphatase 2A, complement component 4, and APOE genotype linked to Alzheimer disease using a systems biology approach. Alzheimer Dement 2022; 18:2042-2054.
Blood and brain transcriptome analysis reveals APOE genotype-mediated and immune-related pathways involved in Alzheimer disease
Panitch R, Hu J, Xia W, Bennett DA, Stein TD, Farrer LA, Jun GR. Blood and brain transcriptome analysis reveals APOE genotype-mediated and immune-related pathways involved in Alzheimer disease. Alzheimers Res Ther. 2022; 14(1):30.
Tau phosphorylation sites serine202 and serine396 are differently altered in chronic traumatic encephalopathy and Alzheimer’s disease
Stathas S, Alvarez VE, Xia W, Nicks R, Meng G, Daley S, Pothast M, Shah A, Kelley H, Esnault C, McCormack R, Dixon E, Fishbein L, Cherry JD, Huber BR, Tripodis Y, Alosco ML, Mez J, McKee AC, Stein TD. Tau phosphorylation sites serine202 and serine396 are differently altered in chronic traumatic encephalopathy and Alzheimer's disease. Alzheimers Dement. 2021 Dec 2.